Wholomics, a startup leveraging metabolic, lipidomic, and lipoproteomic serum signatures via a nuclear magnetic resonance platform, presents promising multi-cancer detection capabilities. Early validation data presented at ASCO indicate the platform's ability to identify multiple tumor types, including notoriously challenging pancreatic cancer, with enhanced sensitivity through functional biomarker profiling rather than tumor DNA analysis. Founded by researchers with backgrounds at Dana Farber and UCL, Wholomics aims to complement current cancer screening methods by focusing on tumor microenvironment-induced metabolic changes.